STIM Neuronetics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of NeuroStar Advanced Therapy System, a non-invasive TMS treatment for MDD and OCD, plus operation of Greenbrook mental health treatment centers
• • New emphasis on fully integrated care via Greenbrook acquisition, adding 93 clinics and SPRAVATO treatment for treatment-resistant depression
• • Strategic shift to vertically integrated provider of mental health solutions combining product and service, aiming for market consolidation and expanded patient access
• • Revenue $149.2M in 2025, up 99% YoY; increased U.S. clinic revenues to 59% from 6% prior year due to Greenbrook acquisition; 658 employees as of December 2025
• • Noteworthy Greenbrook restructuring closing dozens of underperforming clinics and focus on Regional Account Managers to build referral pathways

Risk Factors

• • Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT
• • Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification
• • Regular assessment using industry-standard KPIs for prevention, detection, mitigation, and remediation of cybersecurity incidents

Management Discussion & Analysis

• • Revenue $149.2M in 2025, up 99% YoY from $74.9M in 2024; U.S. revenue $146.0M up 101% YoY; international $3.1M up 29% YoY
• • Gross margin 48.5% in 2025 vs 72.3% in 2024, decline due to Greenbrook clinic business inclusion and reduced treatment session revenue
• • Best performing segment: Clinic revenue $87.0M (59% of US revenues) in 2025 vs $4.4M (6%) in 2024; Worst: NeuroStar System revenue $14.3M (10%) in 2025 vs $15.3M (21%) in 2024
• • Operating loss improved to $(31.4)M from $(34.6)M; net loss $(39.1)M vs $(43.7)M; cash $28.1M with operating cash flow negative $20.4M; $70M debt outstanding; raised $26.8M net via equity offerings and ATM
• • Management expects clinic revenue growth in 2026; anticipates decreased sales/marketing expense but increased general/administrative expense; key risks include financing availability and regulatory challenges

What are the latest STIM SEC filings in 2026?

Neuronetics, Inc. (STIM) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 20, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did STIM file its most recent 10-K annual report?

Neuronetics, Inc. (STIM) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view STIM 10-Q quarterly reports?

Neuronetics, Inc. (STIM)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every STIM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has STIM filed recently?

Neuronetics, Inc. (STIM)'s most recent 8-K was filed on July 20, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find STIM insider trading activity (Form 4)?

SignalX aggregates every STIM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does STIM file with the SEC?

Neuronetics, Inc. (STIM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new STIM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Neuronetics, Inc. (STIM).

What is STIM's SEC CIK number?

Neuronetics, Inc. (STIM)'s SEC CIK (Central Index Key) number is 1227636. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1227636 to look up all STIM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find STIM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Neuronetics, Inc. (STIM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.